Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.60)
# 191
Out of 5,112 analysts
117
Total ratings
54.39%
Success rate
31.24%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.67 | +259.28% | 3 | Dec 2, 2025 | |
| KOD Kodiak Sciences | Maintains: Buy | $24 → $26 | $26.38 | -1.44% | 7 | Nov 17, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.57 | +1,311.93% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $37.00 | +51.35% | 13 | Nov 12, 2025 | |
| FBLG FibroBiologics | Maintains: Buy | $10 → $5 | $0.26 | +1,816.44% | 7 | Nov 5, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $16.28 | +59.71% | 11 | Oct 31, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $35.07 | +25.46% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $77.48 | +13.58% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $8.31 | +44.40% | 7 | Aug 15, 2025 | |
| LYRA Lyra Therapeutics | Reiterates: Neutral | $16 | $3.72 | +330.11% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $17.07 | +228.06% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.98 | +304.04% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $5.68 | +76.06% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.01 | +99.60% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $21.49 | +48.91% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $8.69 | +314.27% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $452.46 | -93.81% | 1 | Aug 22, 2023 |
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $6
Current: $1.67
Upside: +259.28%
Kodiak Sciences
Nov 17, 2025
Maintains: Buy
Price Target: $24 → $26
Current: $26.38
Upside: -1.44%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.57
Upside: +1,311.93%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $37.00
Upside: +51.35%
FibroBiologics
Nov 5, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $0.26
Upside: +1,816.44%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $16.28
Upside: +59.71%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $35.07
Upside: +25.46%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $77.48
Upside: +13.58%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $8.31
Upside: +44.40%
Lyra Therapeutics
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $3.72
Upside: +330.11%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $17.07
Upside: +228.06%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.98
Upside: +304.04%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.68
Upside: +76.06%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.01
Upside: +99.60%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $21.49
Upside: +48.91%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $8.69
Upside: +314.27%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $452.46
Upside: -93.81%